The Lancet · Online First· Shaodong Hong, Ting Zhou, Xue Hou, Xiangjiao Meng, Zhihuang Hu, Wei Zheng, Jiuwei Cui, Yongzhong Luo, Lin Wu, Meijuan Huang, Haipeng Xu, Jie Hu, Yanqiu Zhao, Wenxiu Yao, Yonggui Hong, Jun Cai, Yu Zhang, Chunxia Su, Conghua Xie, Ruoyu Wang, Xiang Li, Qiong He, Liang Zhang, Ruiling Ning, Daren Lin, Tongmei Zhang, Tienan Yi, Liqiang Zhong, Siyuan Huang, Hui Zhao, Jian Fang, Qing Bu, Bihui Li, Zhiye Zhang, Meiqi Shi, Jianhua Shi, Zhiping Deng, Yi Zhu, Hai Zhu, Sa Xiao, Lei Yang, Ni Song, Wenfeng Fang, Li Zhang, Yunpeng Yang, PANKU-Lung01 Investigators·· 3 小时前精选AI 评分61
PANKU-Lung01：Izalontamab brengitecan较含铂化疗延长第三代EGFR TKI治疗后进展肺癌患者的无进展生存期
[Articles] Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China
AI 导读
PANKU-Lung01显示，Izalontamab brengitecan（iza-bren）较含铂化疗显著延长第三代EGFR酪氨酸激酶抑制剂治疗后进展的EGFR突变晚期非鳞状非小细胞肺癌患者的无进展生存期。
推荐理由
该试验将无进展生存期获益与更高的重度治疗相关不良事件发生率并列呈现，为这一经治人群的获益风险权衡提供依据。
来源：The Lancet · Online First · thelancet.com